Cross-Sector entity
STAT News is most often covered alongside Donald Trump, which appears in 2 of these 8 stories. That works out to roughly 0.3 stories per week across a 189-day span. The busiest single day carried 2. The clearest coverage concentration is regulation: 3 of 8 stories, with the rest divided among 4 other categories.
8 verified stories tracked
Last mentioned: Sep 14, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 37 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
STAT News is most often covered alongside Donald Trump, which appears in 2 of these 8 stories. That works out to roughly 0.3 stories per week across a 189-day span. The busiest single day carried 2. The clearest coverage concentration is regulation: 3 of 8 stories, with the rest divided among 4 other categories. STAT News appears in 8 tracked Cross-Sector stories published from March 10, 2026 through September 14, 2026. The tracked stories average 2.3 original sources each. 50% of these stories carry negative sentiment.
Computed from the 8 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering STAT News. Shared-story counts are live from our verified record — not editorial picks.
Expected FDA submission
Lilly plans to file retatrutide for FDA approval.
State and local death toll diverges from CDC
As of Sunday, state and local officials had reported three measles-related deaths, a figure that did not square with CDC data, highlighting a surveillance or reporting discrepancy.
Third measles-related death reported
A 40-year-old Jefferson County woman died from complications associated with measles, according to Jefferson County Coroner Greg Furlong. Her vaccination status was not disclosed.
Pennsylvania reports 676 measles cases
The state health department counted 676 measles cases across 37 counties, 124 hospitalizations, and 4 cases among vaccinated individuals as of Friday.
Coroner releases death details
Lancaster County Coroner Stephen Diamantoni confirmed details to the CDC and public, saying he reported his conclusions to the CDC in response to a state right-to-know request.
Hartford Courant reports Trump picks Overton
The Hartford Courant reports Trump picks Dr. Heidi Overton, a top White House aide, to lead the FDA.
Mary Stoltzfus dies at 6 weeks old
Mary Stoltzfus died at home. She had Amish lethal microcephaly and a measles infection killed her, the coroner told the Associated Press.
Ivan Miller dies shortly after birth
Ivan Miller died from a ruptured spleen. Measles was listed on the death certificate as a contributing factor but did not cause the spleen rupture, according to Coroner Stephen Diamantoni.
Early access program announced
Lilly announced an expanded access program for retatrutide, allowing eligible patients to receive the drug before FDA approval.
Two measles-related infant deaths reported
A newborn boy died shortly after birth from a ruptured spleen, with measles listed as a significant condition but not the cause, and a 6-week-old girl with Amish lethal microcephaly died due to measles. Both infants were too young for the first measles vaccine dose.
80-week trial results released
Lilly reported 22.6% average weight loss with highest retatrutide dose in adults with severe obesity and heart disease.
Clinical Data Release
Early data for FSHD and DM1 therapies reported by STAT and Endpoints News.
Options Surge
Traders purchase large volumes of call options following the clinical updates.
Price Target Update
Brokerages adjust targets, including a raise to $9.00 by some analysts.
STAT Analysis Released
Data confirms a 35% nosedive in Big Pharma antimicrobial R&D over the preceding 60 months.
Financial Results
Sarepta files results of operations and financial condition with the SEC.
Small Biotech Crisis
A wave of bankruptcies among small antibiotic developers highlights the 'broken market' for new treatments.
Market Exit Acceleration
Several large pharma entities announce the closure of infectious disease units to focus on chronic therapies.
Baseline Period
Major drugmakers maintain active antimicrobial pipelines before a steady five-year decline begins.
A third measles-related death in Pennsylvania—a 40-year-old woman—signals a widening outbreak with 676 cases across 37 counties and 124 hospitalizations. Health systems and public health agencies now face both infant and adult severe cases, with vaccination status and federal-state data discrepancies adding complexity.
Source: MedPage Today · STAT News
Pennsylvania's coroner confirms measles directly killed a 6-week-old with a fatal genetic disorder, while a newborn's death was due to a ruptured spleen, not the virus. The distinctions carry major weight for CDC classification and outbreak response.
Source: MedPage Today · STAT News
Reports that Dr. Heidi Overton will be nominated to lead FDA introduce new regulatory uncertainty for health IT vendors, medical device manufacturers, and digital health companies. As a White House adviser without a public FDA track record, her stance on software-as-a-medical-device, telehealth, and AI-enabled diagnostics is unclear. Health technology leaders should monitor confirmation and early policy signals.
Biotech and pharma investors and executives face a potentially new FDA commissioner with no public drug-review track record. If Dr. Heidi Overton is confirmed, her priorities could reshape clinical trial standards, accelerated approval pathways, and review timelines. Early signals from the White House and confirmation hearings will matter most.
Source: abc7news.com · STAT News
Eli Lilly opens an expanded access program for its triple-agonist retatrutide, offering a potential lifeline to patients with refractory obesity and multiple complications who cannot wait for FDA approval. The program highlights ongoing access gaps in obesity care and the need for real-world evidence.
Source: gdnonline.com · 933thedrive.com
Traders have flooded Sarepta Therapeutics with call options following positive early-stage data for its RNA-based rare disease therapies. This surge in bullish sentiment suggests high market confidence in the company's clinical pipeline expansion beyond its core Duchenne muscular dystrophy franchise.
A new analysis reveals a 35% decline in antimicrobial R&D by major pharmaceutical companies over the last five years, highlighting a deepening crisis in the fight against drug-resistant superbugs. The exodus of large-scale investment underscores the persistent lack of economic incentives for developing life-saving antibiotics.
A new analysis reveals a 35% decline in antimicrobial R&D among the world's largest pharmaceutical companies over the last five years. This retreat highlights a deepening crisis in the antibiotic market, where low returns on investment are driving major players toward more lucrative therapeutic areas.
